Riociguat is the first oral, soluble guanylate cyclase stimulator licensed for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension [1] [2] [3] . For some patients with PAH, e.g. children and the elderly, swallowing tablets may be inappropriate or difficult; therefore, oral suspension and crushed tablet formulations of riociguat were developed. Here we present data from two single-centre, randomised, non-blinded, crossover studies evaluating the relative bioavailability of riociguat as oral liquid and standard "immediate release" (IR) oral tablet under fed and fasted conditions, and as a crushed-tablet preparation versus oral tablet under fasted conditions.
Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food 
Background
Riociguat is the first oral, soluble guanylate cyclase stimulator licensed for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension [1] [2] [3] . For some patients with PAH, e.g. children and the elderly, swallowing tablets may be inappropriate or difficult; therefore, oral suspension and crushed tablet formulations of riociguat were developed. Here we present data from two single-centre, randomised, non-blinded, crossover studies evaluating the relative bioavailability of riociguat as oral liquid and standard "immediate release" (IR) oral tablet under fed and fasted conditions, and as a crushed-tablet preparation versus oral tablet under fasted conditions.
Methods
In Study 1, 30 healthy male and female volunteers received five single doses of riociguat in a randomised order: 0.3 and 2.4 mg riociguat (0.15 mg/mL suspension), 0.15 mg riociguat (0.03 mg/mL suspension), and 1.0 mg riociguat IR tablet (all in a fasted state), and 2.4 mg riociguat (0.15 mg/mL suspension) after a highcalorie breakfast. In Study 2, 25 healthy male volunteers received four single doses of riociguat 2.5 mg in a randomised order: oral IR tablet with water and crushed tablet suspended in applesauce or crushed tablet suspended in water (all fasted), and oral whole IR tablet after a continental breakfast. Repeated blood samples for pharmacokinetic assessment were taken. Both studies also assessed safety and tolerability.
Results
In Study 1, dose-normalised pharmacokinetic parameters of riociguat suspensions were almost identical to the standard 1.0 mg IR tablet in fasted conditions (Table 1) ; 90% confidence intervals for the ratio 'suspension/IR tablet' area under concentration (AUC) versus time curve and maximum drug concentration in plasma (C max ) of riociguat were within the bioequivalence reference range (80-125%). After food intake, dose-normalised AUC and C max decreased by 15% and 38%, respectively. In Study 2, riociguat exposure of the 2.5 mg IR tablet was similar for all four modes of administration (Table 2) ; AUC ratios 'crushed tablet suspended in water or applesauce/IR tablet' were within bioequivalence criteria. C max was increased by 17% after administration of crushed tablet suspended in water.
Food intake decreased C max of riociguat IR tablet by 16% with unaltered AUC versus the fasted state. The most frequently reported drug-related adverse events (AEs) were related to riociguat mode of action, notably headache (Study 1: 30-47%; Study 2: 13-20%). There were no deaths, serious AEs or withdrawals owing to AEs.
Conclusions
Riociguat bioavailability was similar between the high-(0.15 mg/mL) and low-(0.03 mg/mL) concentration suspensions and the IR tablet. Riociguat exposure was also similar between whole IR tablet and the crushed tablet suspended either in water or applesauce. Minor food effects were observed for the high-concentration (2.4 mg) suspension and the 2.5 mg IR tablet, but overall the pharmacokinetic results suggest that riociguat formulations are interchangeable. 
